ARS Pharmaceuticals, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $84.3 | $89.1 | $<0.1 | $1.3 | $5.5 |
| Operating income | -$179.4 | -$3.1 | -$67.5 | -$35.5 | -$19.5 |
| Net income | -$171.3 | $8.0 | -$54.4 | -$34.7 | -$20.2 |
| Cash Flow Statement | |||||
| Free cash flow | -$171.2 | $13.0 | -$59.4 | -$40.3 | -$17.6 |
Shares outstanding 99.4M · Free float 46.4%
Annual filing data through FY ended December 31, 2025; float as of October 3, 2026.